Clover Health Investments, Corp. (NASDAQ:CLOV) General Counsel Karen Soares Sells 52,500 Shares

Clover Health Investments, Corp. (NASDAQ:CLOV) General Counsel Karen Soares sold 52,500 shares of Clover Health Investments stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $3.80, for a total value of $199,500.00. Following the completion of the transaction, the general counsel now owns 1,299,663 shares of the company’s stock, valued at approximately $4,938,719.40. This trade represents a 3.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Clover Health Investments Price Performance

Clover Health Investments stock opened at $3.64 on Monday. Clover Health Investments, Corp. has a 1-year low of $0.61 and a 1-year high of $4.87. The stock has a market cap of $1.82 billion, a PE ratio of -18.20 and a beta of 2.00. The stock’s fifty day moving average is $4.08 and its two-hundred day moving average is $3.62.

Institutional Trading of Clover Health Investments

Hedge funds and other institutional investors have recently bought and sold shares of the business. Graypoint LLC acquired a new stake in Clover Health Investments in the fourth quarter valued at $632,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Clover Health Investments in the third quarter valued at $1,228,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Clover Health Investments by 75.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,128,171 shares of the company’s stock valued at $3,181,000 after buying an additional 485,987 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Clover Health Investments in the third quarter valued at $448,000. Finally, State Street Corp raised its stake in Clover Health Investments by 65.0% in the third quarter. State Street Corp now owns 2,189,380 shares of the company’s stock valued at $6,174,000 after buying an additional 862,621 shares in the last quarter. 19.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Canaccord Genuity Group lifted their target price on Clover Health Investments from $4.20 to $4.50 and gave the company a “buy” rating in a report on Monday, March 3rd. Craig Hallum assumed coverage on Clover Health Investments in a report on Tuesday, December 17th. They issued a “buy” rating and a $6.00 target price for the company.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.